A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Condition(s):Muscle Invasive Bladder CancerLast Updated:September 13, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Muscle Invasive Bladder CancerLast Updated:September 13, 2022Completed
Condition(s):Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma; Stage III Bladder Urothelial CarcinomaLast Updated:February 20, 2024Recruiting
Condition(s):Bladder Cancer; Nutrition Aspect of CancerLast Updated:November 20, 2017Unknown status
Condition(s):Bladder CancerLast Updated:October 4, 2022Completed
Condition(s):Bladder CancerLast Updated:March 23, 2022Unknown status
Condition(s):Urothelial CarcinomaLast Updated:December 30, 2021Terminated
Condition(s):Muscle Invasive Bladder CarcinomaLast Updated:August 19, 2022Withdrawn
Condition(s):Bladder CancerLast Updated:May 10, 2023Recruiting
Condition(s):NMIBCLast Updated:July 13, 2023Recruiting
Condition(s):Muscle-invasive Urothelial Cancer of the BladderLast Updated:November 14, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.